Insider Selling: Sarepta Therapeutics Inc. (SRPT) CEO Sells 24,557 Shares of Stock
Sarepta Therapeutics Inc. (NASDAQ:SRPT) CEO Edward M. Md Kaye sold 24,557 shares of the stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total value of $736,710.00. Following the transaction, the chief executive officer now owns 76,983 shares of the company’s stock, valued at $2,309,490. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Sarepta Therapeutics Inc. (NASDAQ:SRPT) opened at 28.15 on Friday. Sarepta Therapeutics Inc. has a 1-year low of $8.00 and a 1-year high of $41.97. The firm has a 50-day moving average price of $26.64 and a 200 day moving average price of $20.72. The stock’s market cap is $1.35 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by $0.16. During the same quarter last year, the business earned ($0.87) earnings per share. On average, equities research analysts anticipate that Sarepta Therapeutics Inc. will post ($5.16) EPS for the current fiscal year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/17/insider-selling-sarepta-therapeutics-inc-srpt-ceo-sells-24557-shares-of-stock.html
Institutional investors have recently made changes to their positions in the stock. State Street Corp raised its position in shares of Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock valued at $48,168,000 after buying an additional 865,658 shares during the period. Franklin Resources Inc. acquired a new position in shares of Sarepta Therapeutics during the first quarter valued at approximately $13,506,000. A.R.T. Advisors LLC acquired a new position in shares of Sarepta Therapeutics during the first quarter valued at approximately $7,461,000. Eagle Asset Management Inc. acquired a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $6,756,000. Finally, Emerald Mutual Fund Advisers Trust acquired a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $4,712,000. 72.09% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have recently commented on SRPT shares. Leerink Swann reiterated an “underperform” rating and set a $5.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, August 4th. Vetr downgraded Sarepta Therapeutics from a “hold” rating to a “sell” rating and set a $17.28 target price for the company. in a research report on Monday, May 23rd. Robert W. Baird reiterated an “outperform” rating and set a $23.00 target price on shares of Sarepta Therapeutics in a research report on Monday, July 18th. Oppenheimer Holdings Inc. reiterated an “outperform” rating and set a $60.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, July 26th. Finally, JMP Securities reiterated an “underperform” rating and set a $10.00 target price on shares of Sarepta Therapeutics in a research report on Thursday. Five investment analysts have rated the stock with a sell rating, seven have given a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $25.60.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.